Reviva Pharmaceuticals (NYSE: RVPH) — Company Overview, News & Financial Data
Reviva Pharmaceuticals develops innovative therapies for unmet medical needs in multiple disease areas.
Reviva Pharmaceuticals
Reviva Pharmaceuticals (NASDAQ:RVPH) is a biopharmaceutical company engaged in the development of innovative therapies for patients with diseases that have significant unmet medical needs, focusing on areas such as the central nervous system, respiratory, cardiovascular, metabolic, and inflammatory diseases. Reviva is committed to the discovery and development of new medications aimed at bettering patient outcomes and providing significant improvements over existing therapies. The company's primary objectives include advancing its lead drug candidates through clinical trials, securing partnerships for distribution and marketing, and constantly expanding its pipeline through research and development to address a wide range of medical conditions.
Snapshot
Operations
Products and/or services of Reviva Pharmaceuticals
- Development of Brilaroxazine, a novel therapy targeting schizophrenia and pulmonary arterial hypertension.
- Research into innovative treatments for major depressive disorder.
- Portfolio expansion in the CNS disorder treatments.
- Advancements in therapies for chronic cough.
- Investigation of solutions for acute respiratory distress syndrome.
- Exploratory projects in the treatment of Parkinson’s disease.
Reviva Pharmaceuticals executive team
- Dr. Laxminarayan Bhat Ph.D.Founder, CEO, President & Director
- Mr. Narayan PrabhuChief Financial Officer